Overview

Phase 3 Study of KHK7580

Status:
Completed

Trial end date:
2016-12-28

Target enrollment:

Participant gender:

Summary

This long-term study is designed to evaluate safety and efficacy of KHK7580 orally administered once daily for 52 weeks for patients with secondary hyperparathyroidism receiving hemodialysis.

Phase:

Phase 3

Details

Lead Sponsor:

Kyowa Hakko Kirin Co., Ltd
Kyowa Kirin Co., Ltd.